To read the full story
Related Article
- Takeda Submits Plans to Improve Business Practices
July 13, 2015
- Takeda to Submit Plans to Improve Business Operations after MHLW Order
June 15, 2015
- No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ.
March 2, 2015
- Takeda Directors Face 3-Month Pay Cut over CASE-J Issue
October 6, 2014
- MHLW to Conduct Hearings over CASE-J Study, Take “Appropriate Action” against Takeda: Minister
June 27, 2014
- Probe Finds Takeda’s Systematic Involvement in CASE-J Study, No Data Tampering
June 23, 2014
- JPMA Urges Takeda to Improve Promotion Regime over CASE-J
March 24, 2014
- Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
- MHLW to Conduct Hearings with Takeda on Blopress Research Data
March 5, 2014
- Takeda Extended 3.7 Billion Yen in CASE-J-Linked Grants to Kyoto Univ., 2 Entities; “No COI” Says Pres. Hasegawa
March 4, 2014
- Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
- Japanese Cardiologist Raises Statistical Concerns over CASE-J Study in US Journal
February 28, 2014
- Takeda Offered 600 M. Yen in Grants to Kyoto University Involved in CASE-J Study, Where Ex-Employee Affiliated
December 5, 2013
REGULATORY
- Pharma Renews Call for Abolishing Off-Year Revisions, but MHLW Stays Put with Honebuto
November 22, 2024
- Pharma Pushes to Scrap Off-Year Revisions; LDP Members Urge Fresh Talks by 4 Ministers
November 22, 2024
- Health Minister Committed to Drug Supplies, Repeats Plan to Base Off-Year Debate on Honebuto
November 21, 2024
- DPP Requests Promotion Self-Medication Tax Break in 3-Way Talks
November 21, 2024
- 3 Parties Reach Deal on Economic Plan, Off-Year “Abolition” Not Spelled Out
November 21, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…